Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Common Equity: 2021-2025

Historic Common Equity for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $535.4 million.

  • Kiniksa Pharmaceuticals International's Common Equity rose 22.51% to $535.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $535.4 million, marking a year-over-year increase of 22.51%. This contributed to the annual value of $438.4 million for FY2024, which is 0.09% down from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Common Equity stood at $535.4 million, which was up 8.16% from $495.0 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Common Equity peaked at $535.4 million during Q3 2025, and registered a low of $153.5 million during Q2 2022.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Common Equity value was $437.0 million (recorded in 2024), while the average stood at $443.3 million.
  • Its Common Equity has fluctuated over the past 5 years, first crashed by 38.59% in 2022, then skyrocketed by 168.19% in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Common Equity (Quarterly) stood at $185.0 million in 2021, then surged by 114.09% to $396.1 million in 2022, then rose by 10.78% to $438.8 million in 2023, then decreased by 0.09% to $438.4 million in 2024, then climbed by 22.51% to $535.4 million in 2025.
  • Its Common Equity stands at $535.4 million for Q3 2025, versus $495.0 million for Q2 2025 and $457.5 million for Q1 2025.